Combination therapy for severe drug-resistant pneumonia
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new approach combining a traditional Chinese medicine formula with bacteriophages (viruses that attack bacteria) to treat severe pneumonia caused by antibiotic-resistant bacteria. It aims to see if this combination can improve outcomes for patients who have limited treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have severe pneumonia caused by drug-resistant bacteria (specifically Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa).
- You meet the traditional Chinese medicine diagnosis of qi deficiency, toxin accumulation, and blood stasis.
- You agree to have samples taken from your airways and to undergo a bronchoscopy with lung washing.
- You agree to receive the bacteriophage therapy as a mist you inhale.
- You are not pregnant or breastfeeding, do not have a weakened immune system, and have not been on a ventilator for more than 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a Chinese herbal formula combined with virus-based therapy (bacteriophages) to treat severe pneumonia caused by antibiotic-resistant bacteria. It may offer a new option when standard antibiotics fail.
This trial tests a combination of traditional Chinese and Western medicine for adults with severe pneumonia caused by bacteria that are resistant to multiple antibiotics. It aims to see if this combined approach can improve treatment outcomes.
This trial tests whether adding traditional Chinese medicine to standard care helps people with pneumonia caused by bacteria that are hard to treat with many antibiotics. It may offer another option to fight the infection.
This study tests a new treatment that combines regular antibiotics with a special virus that attacks bacteria (called a phage) to fight lung infections that do not respond to standard antibiotics. It aims to see if this combination is safe and might help people with cystic fibrosis who have stubborn lung infections.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Hear when a new Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.